Study #2022-0268
NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)
MD Anderson Study Status
Enrolling
Treatment Agent
mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFOX6 6 month, CAPOX 6 month, mFOLFIRINOX
Description
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Stage III Colon Cancer
Study phase:
Phase II/III
Physician name:
Arvind Nageshwara Vijaya Dasari
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-833-945-1429
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.